BIOSU BioPlus Acquisition Corporation

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 001-41116

 

BioPlus Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

260 Madison Avenue

Suite 800

New York, New York 10026

(212) 287-4092

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant

Class A Ordinary Shares, par value $0.0001 per share

Warrants, each exercisable for one Class A Ordinary Share for $11.50 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)	☒
Rule 12g-4(a)(2)	☐
Rule 12h-3(b)(1)(i)	☒
Rule 12h-3(b)(1)(ii)	☐
Rule 15d-6	☐
Rule 15-22(b)	☐

 

Approximate number of holders of record as of the certification or notice date: 1

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, BioPlus Acquisition Corp. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Dated: October 16, 2023

 

	BIOPLUS ACQUISITION CORP.
	By:	/s/ Ross Haghighat
	Name:	Ross Haghighat
	Title:	Chief Executive Officer and Chief Financial Officer

 

 

 

 

---